DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole

NCT01733823 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

31

Enrollment

NETWORK

Sponsor class

Conditions

HNSCC,Larynx, Pharynx and Oral Cavity

Interventions

RADIATION: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole

Sponsor

Danish Head and Neck Cancer Group